Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Hervé Tilly, Chloé Antier et al.|Blood Advances|2021Cited by 51
R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa CentersVincent Camus, Hervé Tilly, Alina Berriolo-Riedinger et al.|Blood|2020Cited by 3
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell LymphomaJuliette Pénichoux, Vincent Camus, Pierre Decazes et al.|Hematological Oncology|2025Cited by 1
OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDYVincent Camus, Hervé Tilly, Cédric Rossi et al.|Hematological Oncology|2021Cited by 0
13 | PROGNOSTIC VALUE OF THE COMBINATION OF RADIOMICS PARAMETERS MEASURED ON BASELINE FDG PET/CT IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMAPierre Decazes, Vincent Camus, Cédric Rossi et al.|Hematological Oncology|2025Cited by 0